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Summary 
Background Interleukin-17A (IL-17A) is a proinflammatory cytokine implicated in the 
pathogenesis of psoriatic arthritis (PsA). We assessed the efficacy and safety of 
subcutaneous treatment with secukinumab, a human anti-IL-17A monoclonal antibody, in 
patients with PsA. 
Methods In this phase 3, double-blind, placebo-controlled study conducted at 76 centers 
worldwide, adults with active PsA were randomized (1:1:1:1) via computer-generated blocks 
to receive subcutaneous placebo or secukinumab 300mg, 150mg, or 75mg weekly from 
baseline, and then every 4 weeks from week 4. The primary endpoint was the proportion of 
patients achieving a ≥20% improvement in American College of Rheumatology response 
criteria (ACR20) at week 24. This study is registered with ClinicalTrials.gov (NCT01752634). 
Findings Between April and November 2013, 397 patients were randomly assigned to 
receive secukinumab 300mg (n=100), 150mg (n=100), 75mg (n=99), or placebo (n=98). A 
significantly higher proportion of patients achieved an ACR20 response at week 24 with 
secukinumab 300mg (54/100 [54·0%]; odds ratio versus placebo [OR] 6.81, 95% confidence 
interval [CI] 3.42–13.56; p<0·0001), 150mg (51/100 [51·0%]; OR 6.52, 95% CI 3.25–13.08; 
p<0·0001), and 75mg (29/99 [29·3%]; OR 2.32, 95% CI 1.14-–4.73; p=0·0399), versus 
placebo (15/98 [15·3%]).  Through week 16 the most common adverse events were upper 
respiratory tract infections (4.0%, 8.0%, 10.1% and 7.1% with secukinumab 300mg, 150mg, 
and 75mg, and placebo, respectively) and nasopharyngitis (6.0%, 4.0%, 6.1% and 8.2%, 
respectively). Serious adverse event rates through week 16 were 5.0%, 1.0% and 4% with 
secukinumab 300mg, 150mg and 75mg, respectively, compared with 2.0% with placebo. No 
deaths were reported.  
Interpretation Subcutaneous treatment with secukinumab 300mg and 150mg improved the 
signs and symptoms of PsA, suggesting this agent as a potential future treatment option. 
Funding Novartis Pharma AG.  
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Introduction 
Psoriatic arthritis (PsA), a chronic inflammatory disease that can affect peripheral and axial 
joints, entheses, and the skin, is associated with impaired physical function and poor quality 
of life.1,2 Pathogenesis-based interventions, particularly therapies targeting tumor necrosis 
factor (TNF), have improved outcomes in PsA patients.3–7 Recently, the interleukin (IL)-12/23 
inhibitor ustekinumab and the phosphodiesterase-4 inhibitor apremilast have also 
demonstrated efficacy.8–10 Despite this progress, not all patients respond to or tolerate 
therapy, and significant unmet clinical needs remain. 
IL-17A and its requisite receptor are expressed in synovial tissues and as such the IL-17 
pathway is proposed to contribute to PsA pathogenesis.11–15 IL-17A can mediate a variety of 
effector biologic functions that can result in joint and enthesial inflammation, damage, and 
tissue remodeling.16  
Secukinumab, a human, monoclonal antibody that inhibits the effector function of IL-17A, 
has been shown to be superior to placebo and etanercept in improving psoriasis signs and 
symptoms.17 In the recent phase 3 FUTURE 1 study conducted in 606 PsA patients, 
intravenous (iv) loading with secukinumab followed by subcutaneous (sc) maintenance 
dosing significantly improved key clinical domains of disease versus placebo, including signs 
and symptoms, radiographic disease progression, physical functioning, and quality of life.18  
We report the primary results from FUTURE 2 (NCT01752634), an ongoing phase 3 trial 
assessing the efficacy and safety of subcutaneous loading and maintenance dosing of 
secukinumab in PsA.  
 
Methods    
Study design 
This randomized, double-blind, placebo-controlled phase 3 trial was conducted at 76 centers 
across Asia, Australia, Europe, and North America. All centers received approval from 
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independent ethics committees or institutional review boards. The study was carried out in 
accordance with the principles of the Declaration of Helsinki. Changes to the protocol after 
commencement of the study are summarized in the supplementary appendix. The study 
protocol is available from the sponsor.  
Patients 
Patients were aged ≥18 years, fulfilled the ClASsification criteria for Psoriatic ARthritis 
(CASPAR) and had active disease, defined as ≥3 tender joints and ≥3 swollen joints, despite 
previous treatment with nonsteroidal anti-inflammatory drugs, disease-modifying 
antirheumatic drugs, and/or anti-TNF agents. Concomitant oral corticosteroids (≤10 mg/day 
prednisone or equivalent) and methotrexate (≤25 mg/week) were permitted provided the 
dose was stable for ≥2 and ≥4 weeks prior to randomization, respectively. Patients who had 
previously used up to 3 anti-TNF agents could enroll if they had experienced an inadequate 
response or stopped treatment due to safety or tolerability reasons (anti–TNF-IR). Anti-TNF 
therapy required a washout period of 4–10 weeks prior to randomization, depending upon 
the agent’s half-life. Key exclusion criteria included previous use of any biologic other than 
anti-TNF agents; active inflammatory diseases other than PsA; active infection in the 2 
weeks prior to randomization, or a history of ongoing, chronic, or recurrent infections; history 
of malignancy (excluding basal cell carcinoma or actinic keratosis, in-situ cervical cancer or 
non-invasive malignant colon polyps); pregnancy. 
Patients provided written informed consent prior to study-related procedures being 
undertaken. 
Randomization and masking 
After a 4-week screening period, patients were randomized (1:1:1:1) to receive sc 
secukinumab 300mg, 150mg, or 75mg, or placebo, weekly from baseline to week 4, and 
every 4 weeks thereafter. At week 16, patients were classified as responders (≥20% 
improvement from baseline in tender and swollen joint counts) or non-responders. Placebo-
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treated patients were re-randomized (1:1) to receive subcutaneous secukinumab 300mg or 
150mg every 4 weeks from week 16 (non-responders) or 24 (responders).   
Randomization was performed using an interactive voice/web response system that 
assigned patients to randomization numbers identifying assigned treatments and unique 
medication numbers for the packages of study treatment to be prepared. Randomization was 
stratified according to prior anti-TNF therapy use, with patients being anti–TNF-naïve 
(planned enrolment approximately 60%) or anti–TNF-IR. Medication numbers were 
accessible only to the unblinded pharmacist or other qualified personnel at each site. Doses 
were prepared from open-label secukinumab or placebo vials by the independent unblinded 
pharmacist or other qualified person and provided in identical syringes of reconstituted 
secukinumab/placebo solutions. Data analysts remained blinded until the week 24 analysis. 
Procedures 
Additional information on the assessments undertaken during the trial is provided in the 
supplementary appendix. Key efficacy, safety, tolerability, and biochemical assessments 
were conducted at screening, baseline, weeks 24 and 52, and timepoints in between. 
Secukinumab immunogenicity was assessed via a MesoScale Discovery bridging assay19 
using blood samples collected at baseline, and at weeks 24 and 52.  
 
Outcomes 
The primary endpoint was the proportion of patients achieving an ACR20 response at week 
24, defined as ≥20% improvement from baseline in: the number of tender and swollen joints 
and at least three of the following five domains: patient’s global assessment; physician’s 
global assessment; pain; disability; and an acute-phase reactant.20 
Secondary endpoints at week 24 were: ≥75% and ≥90% improvement in Psoriasis Area-and-
Severity Index (PASI75 and PASI90)21; change from baseline in 28-joint Disease Activity 
Score using C-reactive protein (DAS28-CRP)22; change from baseline in Medical Outcomes 
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Study 36-item Short-Form Health Survey v2 physical component summary score (SF36-
PCS)23; change from baseline in Health Assessment Questionnaire Disability Index (HAQ-
DI) score24; ACR50 response; resolution of dactylitis and enthesitis; and overall safety and 
tolerability. PASI75 and PASI90 responses were assessed in patients with ≥3% body surface 
area (BSA) affected by psoriasis at baseline. Resolution of dactylitis and enthesitis was 
assessed in patients with these characteristics at baseline, with pooled data (all 
secukinumab groups combined) used for analysis. 
Pre-specified exploratory endpoints included: ACR70 responses; presence of dactylitis and 
enthesitis in each treatment group (unpooled data); primary and secondary efficacy 
assessments at week 52; and subgroup analyses according to prior anti-TNF use. Analysis 
of secukinumab efficacy with and without concomitant methotrexate therapy was conducted 
post-hoc. 
Safety analyses assessed adverse events (AEs), serious AEs (SAEs), and routine laboratory 
values. Biochemical investigations were classified according to the Common Terminology 
Criteria for Adverse Events (CTCAE) v4·03.25  
 
Statistical analyses  
A sample size of 100 patients per group was estimated to provide approximately 92% power 
to detect a treatment difference of 26% for the primary endpoint of ACR20 response at week 
24 by Fisher’s exact test, and approximately 80% power for secondary endpoints. The 
expected treatment difference of 26% for the primary endpoint was based on an expected 
overall placebo response of 21% (weighted average of placebo data in anti–TNF-naïve 
[25%] and anti–TNF-IR [15%] patients from PSUMMIT I and II8,9) and an expected overall 
secukinumab response of 47% (weighted average of expected response in anti–TNF-naïve 
[55%] and anti–TNF-IR [35%] patients). Averages were weighted based on planned 
enrolment of approximately 40% anti–TNF-IR patients. 
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The primary and secondary and relevant pre-specified exploratory endpoints were analyzed 
according to the pre-specified analysis plan using SAS software, Version 9.3.26 Safety data 
are presented at week 16, when all patients remained in the originally randomized groups, 
and across the entire study period; efficacy was assessed at week 24 (primary analysis) and 
up to week 52. A sequential hierarchical testing method was used to maintain the family-
wise type I error rate at 5% across the primary and ranked secondary endpoints. If the 
primary efficacy analysis was statistically significant, secondary analyses were completed in 
the following sequence: ACR20; PASI75; PASI90; DAS28-CRP; SF36-PCS; HAQ-DI; 
ACR50; dactylitis (pooled data across doses); and enthesitis (pooled data across doses) 
(see Supplementary Figure S1 for further details).  
For week 24 analyses of binary variables, patients who switched from placebo to 
secukinumab at week 16 due to non-response were imputed as non-responders at week 24 
(early escape penalty). Week 16 non-responders in secukinumab groups were also 
considered non-responders at week 24. Patients with missing data or who had prematurely 
discontinued were imputed as non-responders. Odds ratios (ORs), 95% confidence intervals 
(CIs) and p-values were computed for comparisons of secukinumab regimens versus 
placebo regimen from a logistic regression model with treatment and prior anti-TNF use as 
factors and baseline weight as a covariate.  Baseline PASI score was a covariate in PASI75 
and PASI90 analyses. 
Analyses of continuous variables at week 24 used a mixed-effects model with treatment 
regimen, analysis visit, and prior anti-TNF use as factors, and weight and baseline score as 
continuous covariates. Treatment by analysis visit and baseline score by analysis visit were 
interaction terms, and an unstructured covariance structure was assumed.  
Inferential analyses (with imputation) and descriptive summaries (observed data) were 
performed on primary and secondary endpoints from week 28 onwards. In the inferential 
analysis of binary variables over this period, patients who withdrew from the study were 
considered non-responders from the time of withdrawal, without the penalty for early escape 
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that was applied in the primary analysis. Efficacy analyses from week 28 onwards include 
only patients originally randomized to secukinumab. 
 
Safety endpoints were evaluated for all patients who received at least one dose of study 
drug and are summarized descriptively. A data monitoring committee reviewed unblinded 
safety data at regular intervals. Potential major adverse cardiac events were adjudicated by 
an independent expert committee. 
 
This study is registered with ClinicalTrials.gov (NCT01752634). 
 
Role of the funding source 
The study was designed by representatives from the scientific steering committee and the 
funding source, Novartis Pharma AG. Data were collected according to Good Clinical 
Practice guidelines by the study investigators. Data and statistical analyses were performed 
by statisticians employed by the funding source. All authors had access to the study data 
and participated in the decision to publish. The corresponding author, with approval from 
coauthors, made the final decision to submit for publication. 
 
Results 
Between April 14 and November 25, 2013, 397 patients were randomly assigned to receive 
secukinumab 300mg (n=100), 150mg (n=100), 75mg (n=99), or placebo (n=98), 373 
(94·0%) of whom completed week 24 (figure 1). No patients were excluded from efficacy and 
safety analyses.  
Baseline demographics, disease characteristics, and prior/concomitant medication usage 
were similar across study groups, except for imbalances in baseline PASI score and the 
proportion of female patients, patients with psoriasis affecting ≥3% BSA, and patients with 
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dactylitis or enthesitis (table 1). Most (65%) patients were anti–TNF-naïve and 47% were 
receiving concomitant methotrexate.   
The primary endpoint was met with all secukinumab doses. ACR20 response rates at week 
24 were significantly higher in the secukinumab 300mg (54/100 [54·0%]; p<0·0001), 150mg 
(51/100 [51·0%]; p<0·0001), and 75mg (29/99 [29·3]%; p=0·0399) groups versus placebo 
(15/98 [15·3%]) (figure 2; table 2).  
Assessing subsequent secondary endpoints in hierarchical order, PASI75 and PASI90 
response rates, and mean changes from baseline in DAS28-CRP and SF36-PCS were all 
significantly higher with secukinumab 300mg and 150mg versus placebo at week 24. 
Secukinumab 300mg significantly improved HAQ-DI (table 2) and ACR50 (figure 2). 
Secukinumab 75mg did not significantly improve PASI75 response versus placebo; thus, 
subsequent endpoints in the hierarchy were not met with this dose. Improvements in 
dactylitis and enthesitis with secukinumab (pooled) versus placebo were not statistically 
significant using the hierarchical analysis since the testing strategy required all other 
endpoints on all doses to be significant in order to test, and this requirement was not met. 
The proportions of patients whose dactylitis and enthesitis resolved at week 24 in each 
individual treatment group are in supplementary table S1. 
In pre-specified exploratory analyses, ACR70 response was achieved by 20/100 (20·0%), 
21/100 (21·0%), and 6/99 (6·1%) patients in the secukinumab 300 mg, 150 mg, and 75 mg 
groups, respectively, compared with 1/98 (1·0%) patient in the placebo group. ACR and 
PASI response rates were higher with secukinumab than placebo in both anti–TNF-naïve 
and anti–TNF-IR patients, with the magnitude of response being higher in the anti–TNF-
naïve population (pre-specified exploratory analysis; table 3). The interaction between 
treatment and anti–TNF-status was tested and was not statistically significant (p=0.24); 
however, clinically meaningful differences were observed between the effect sizes for the 
300mg and 150mg doses in anti–TNF-IR patients. In post-hoc analyses, improvements in 
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ACR response rates were observed with secukinumab versus placebo at week 24, with and 
without concomitant methotrexate use (supplementary table S2). 
At week 52, 335/397 patients (84·4%) remained in the study. Clinical responses observed 
with secukinumab 300 mg and 150 mg across the PsA domains assessed at week 24 were 
maintained through 52 weeks of therapy in patients initially randomized to these treatments 
(supplementary table S3). Using a conservative estimate of efficacy with missing values 
imputed as non-response, ACR20/50/70 response rates at week 52 were 64·0/44·0/24·0%, 
64·0/39·0/20·0%, and 50·5/30·3/16·2% in patients initially randomized to secukinumab 
300mg, 150mg, and 75mg, respectively (figure 2; supplementary table S3). Corresponding 
response rates with observed data were 72·7/50·0/27·3%, 72·7/44·3/22·7%, and 
66·7/40·0/21·3%, respectively. 
No deaths were reported during the study. No reports of suicide or suicidal ideation were 
reported in secukinumab-treated patients. The incidence of AEs during the placebo-
controlled period was similar across study groups, except for a slightly higher incidence of 
SAEs in the secukinumab 300mg and 75mg groups (table 4). Over the entire treatment 
period (mean exposure: secukinumab, 411.7 days; placebo, 130.6 days), the exposure-
adjusted SAE rates were 6·4, 5·1, and 11·2 per 100 patient-years in patients who received 
at least one dose of secukinumab 300mg, 150mg, and 75mg, respectively, compared with 
8·6 amongst placebo-treated patients (table 4). Reported SAEs are listed in supplementary 
table S4. Exposure-adjusted incidence rates of infections and infestations were 78·7, 86·7, 
and 63·7 per 100 patient-years in patients who received secukinumab 300mg, 150mg, and 
75mg, respectively, compared with 108·0 amongst placebo-treated patients. Upper 
respiratory tract infections and nasopharyngitis were the most common infections, occurring 
at similar rates across secukinumab treatment groups. No active tuberculosis cases were 
reported.  
Candida infections were reported in 11 patients, all on secukinumab: six oral candidiasis 
cases (reported in two, three, and one patient in the 300mg, 150mg, and 75mg groups, 
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respectively); four vulvovaginal candidiasis (one in the 300mg group and three in the 150mg 
group), one esophageal candidiasis (300mg group), and one Candida infection (300mg 
group). One patient experienced concurrent vulvovaginal and oral candidiasis (150mg 
group). These events were considered by the investigators to be mild or moderate, resolved 
spontaneously or with oral therapy, and did not lead to study withdrawal.  
There were three cases of squamous cell carcinoma with secukinumab (two in the 75mg 
group and one in the 150mg group). Both cases in the 75mg group resulted in 
discontinuation of study treatment. A myocardial infarction was recorded in a patient with a 
history of sinus tachycardia and ongoing hypertension and hyperlipidemia who received 
secukinumab 75mg. The patient continued in the study. Crohn’s disease was not reported as 
an AE in any patient. One patient receiving secukinumab 300mg experienced hemorrhagic 
diarrhea, which resolved. The patient continued in the study. There were two cases of 
ulcerative colitis (one in the 300mg group which resolved, and one in the  
150mg group which did not resolve). Both patients continued in the study. Transient CTCAE 
grade 3 neutropenia occurred in one patient (300mg group). No patients withdrew from the 
study due to neutropenia. Treatment-emergent (positive during study but negative at 
baseline) anti-secukinumab antibodies were detected in one patient originally randomized to 
placebo who switched to secukinumab 150mg at week 24. There was no loss of efficacy or 
immunogenicity-related AEs reported in this patient. 
 
Discussion 
In this phase 3 trial, sc administration of the anti-IL-17A monoclonal antibody secukinumab 
significantly improved the signs and symptoms of PsA versus placebo. ACR20 response 
rates at week 24 were superior to placebo with all secukinumab groups. Additional efficacy 
outcomes at week 24 also showed significant benefits with secukinumab 300mg and 150mg 
versus placebo, but responses with secukinumab 75mg were lower and not significantly 
different from placebo in the hierarchical analysis. These results confirm and significantly 
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extend the findings of earlier studies with secukinumab in PsA.18 Consistent with the 
psoriasis phase 3 program,17 improvements in psoriasis symptoms in FUTURE 2 were 
greater with secukinumab 300mg than with 150mg.  
While anti-TNF agents improve outcomes in PsA,3–7 many patients still experience 
inadequate disease control and/or are intolerant of these agents. Loss of response over time 
is also clinically problematic. Although responses were generally higher in the anti–TNF-
naïve population, the clinical benefits of secukinumab were observed in both  
anti–TNF-naïve and anti–TNF-IR patients. Secukinumab may offer an additional treatment 
option for both populations.  
The safety profile of secukinumab was consistent with earlier reports of secukinumab in 
PsA8,18 and psoriasis.17 The types and incidence of AEs with secukinumab were comparable 
with placebo at week 16, with no apparent relationship to dose. The rate of discontinuation 
due to AEs with secukinumab was low. There were no deaths in the study. Candida 
infections were more frequent on secukinumab than placebo. IL-17 is important to 
mucocutaneous defense against Candida27 and continued vigilance regarding such 
infections will be required when assessing inhibitors of this pathway. Immunogenicity with 
secukinumab was low and was not associated with a loss of efficacy or immunogenicity-
related AEs. 
This study has several limitations. The pre-defined hierarchical testing procedure adequately 
protected the type I error rate and demonstrated the effectiveness of both the 300mg and 
150mg secukinumab doses for the primary endpoint and multiple ranked secondary 
endpoints. The limitation of this procedure is that it is sensitive to the ordering of the 
endpoints and, as such, clinically relevant results fail to meet statistical significance if a 
preceding ranked endpoint was non-significant. Furthermore, it may not be practical or 
desirable to extend the statistical hierarchy to include every relevant endpoint in a multi-
faceted disease such as PsA. This study did not include assessment of radiographic disease 
progression, but inhibition of radiographic progression has been demonstrated previously 
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with secukinumab.18 This trial was not designed to identify a difference between doses, or to 
examine differences in response according to prior anti-TNF use or concomitant 
methotrexate use. Finally, axial disease was not assessed in FUTURE 2.  
In summary, treatment with secukinumab 300mg or 150mg sc provided significant and 
sustained improvements in key clinical domains of PsA, with a safety profile consistent with 
that seen in other studies with secukinumab. These data provide further evidence that  
IL-17A is an important cytokine in the pathogenesis of PsA, and suggest that secukinumab, 
by providing an alternative mechanism of action to current therapies, may be a useful future 
therapeutic option.  
 
Panel: Research in context 
Evidence before this study 
We searched the PubMed database using the terms “psoriatic arthritis (PsA)”, “biologic”, and 
“interleukin-17 (IL-17)” for English language articles published up to April 2015 with no 
limitation or restriction for year of publication or article type. Increasing clinical and laboratory 
evidence has linked IL-17 to the pathogenesis of immune-mediated inflammatory diseases, 
such as psoriasis and PsA.12–15 Several studies, including large phase 3 studies with 
secukinumab, have demonstrated that inhibiting IL-17 improves signs and symptoms in 
patients with moderate to severe psoriasis,17,28,29 and secukinumab is approved for this 
indication. Recent clinical data have provided evidence for IL-17 inhibition being of 
therapeutic benefit in PsA. A trend towards improvement in clinical response, markers of 
inflammation, and quality of life measures was reported in a phase 2, proof-of-concept study 
evaluating intravenous administration of secukinumab in patients with PsA, although the 
study did not meet its primary endpoint of superior ACR20 response rates versus placebo at 
week 6.8 More recently, a phase 2 study has shown that inhibiting the IL-17 receptor 
improves PsA signs and symptoms.30     
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Added value of this study 
FUTURE 2 is the first large phase 3 study to demonstrate that inhibiting IL-17 with an sc 
dosing regimen provides significant improvements in important clinical domains of PsA, 
including joint and skin symptoms, physical function, and quality of life. Moreover, 52-week 
data from this study suggest that efficacy with secukinumab is sustained over extended 
periods of time. The safety profile of secukinumab in this study was similar to that reported in 
patients with moderate to severe psoriasis.  
Implications of all the available evidence  
Our findings build and expand upon previous reports of IL-17 having an important role in the 
pathogenesis of PsA and suggest that secukinumab may be a suitable alternative biological 
treatment in this disease setting. 
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Figures and tables 
Figure 1: Patient disposition and flow through the trial from screening to week 52 
Screened for eligibility
(N = 469)
Randomized
(N = 397)
Excluded (n = 72)
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Figure 2: ACR20 and ACR50 response rates over time from baseline to week 52  
Missing data were imputed as non-response through week 52. 
*p<0·0001; §p<0·01; ‡p<0·05 vs. placebo. P-values at week 24 were analyzed as part of the 
statistical hierarchy and are adjusted for multiplicity of testing. Response rates over time are 
presented for patients as per the treatment group at randomization.  
ACR20 
 
ACR50 
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Table 1: Baseline characteristics of patients assigned to each treatment group 
Demographic variable 
Secukinumab 
300 mg (n=100) 
Secukinumab                                
150 mg  
(n=100) 
Secukinumab                           
75 mg  
(n=99) 
Placebo  
(n=98) 
Age in years, mean (SD) 
 46·9 (12·6) 46·5 (11·7) 48·6 (11·4) 49·9 (12·5) 
Female, n (%) 49 (49·0) 45 (45·0) 52 (52·5) 59 (60·2) 
Race, n (%) 
White 96 (96·0) 90 (90·0) 90 (90·9) 94 (95·9) 
Black 1 (1·0) 0 (0·0) 0 (0·0) 0 (0·0) 
Asian 2 (2·0) 6 (6·0) 5 (5·1) 1 (1·0) 
Unknown 0 (0·0) 0 (0·0) 1 (1·0) 0 (0·0) 
Other 1 (1·0) 4 (4·0) 3 (3·0) 3 (3·1) 
Weight in kg, mean (SD) 85·4 (18·4) 91·2 (19·8) 85·6 (20·6) 86·2 (19·8) 
Number of prior anti-TNF therapies for PsA, n (%) 
0 67 (67·0) 63 (63·0) 65 (65·7) 63 (64·3) 
1 16 (16·0) 26 (26·0) 21 (21·2) 16 (16·3) 
2 or 3 17 (17·0) 11 (11·0) 13 (13·1) 19 (19·4) 
Methotrexate use at 
randomization, n (%) 44 (44·0) 44 (44·0) 47 (47·5) 50 (51·0) 
Systemic glucocorticoid use 
at randomization, n (%) 18 (18·0) 23 (23·0) 19 (19·2) 21 (21·4) 
Patients with specific disease characteristics, n (%) unless stated 
Psoriasis BSA ≥3% 41 (41·0) 58 (58·0) 50 (50·5) 43 (43·9) 
PASI ≤10 21 (51·2) 25 (43·1) 28 (56·0) 23 (53·5) 
PASI score >10 
 
20 (48·8) 
 
33 (56·9) 
 
22 (44·0) 
 
20 (46·5) 
 
Dactylitis 46 (46·0) 32 (32·0) 33 (33·3) 27 (27·6) 
Dactylitis count,  
mean (SD) 3.6 (3·5)  4.5 (5·1) 3.0 (3·6) 2.7 (2·2) 
Enthesitis 56 (56·0) 64 (64·0) 68 (68·7) 65 (66·3) 
Enthesitis count, 
mean (SD) 2.8 (1·7) 3.2 (1·6) 3.2 (1·7) 3.1 (1·7) 
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Baseline disease and quality of life scores, mean (SD) 
TJC (78 joints) 20·2 (13·3) 24·1 (19·4) 22·2 (16·3) 23·4 (19·0) 
SJC (76 joints) 11·2 (7·8) 11·9 (10·1) 10·8 (9·2) 12·1 (10·7) 
DAS28-CRP 4·8 (1·0) 4·9 (1·1) 4·7 (1·0) 4·7 (1·0) 
PASI 11·9 (8·4) 16·2 (14·3) 12·1 (10·2) 11·6 (8·3) 
Physician’s global 
assessment (VAS) 55·0 (14·7) 56·7 (16·6) 59·0 (17·9) 55·0 (16·0) 
HAQ-DI 1·3 (0·6) 1·2 (0·6) 1·2 (0·6) 1·2 (0·7) 
Pain (VAS) 57·7 (19·0) 58·9 (19·8) 56·7 (21·1) 55·4 (22·1) 
Patient’s global 
assessment (VAS) 60·7 (18·9) 62·0 (19·5) 59·0 (19·1) 57·6 (19·8) 
SF36-PCS 36·9 (8·0) 36·2 (8·1) 36·2 (8·1) 37·4 (8·8) 
 
Mean (SD) reported for those patients with these symptoms at baseline. 
Mean PASI score is from those patients with ≥3% BSA psoriasis 
BSA = body surface area; DAS28-CRP = disease activity score 28 based on C-reactive 
protein; HAQ-DI = health assessment questionnaire disability index; PASI = psoriasis area 
and severity index; PsA = psoriatic arthritis; SD = standard deviation; SF36-PCS = short 
form 36 physical component summary; SJC = swollen joint count; TJC = tender joint count; 
TNF = tumor necrosis factor; VAS = visual analog scale. 
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Table 2: Efficacy of secukinumab versus placebo at week 24 across pre-specified primary and secondary endpoints 
 
Secukinumab 300 mg  
(n=100) 
Secukinumab 150 mg  
(n=100) 
Secukinumab 75 mg  
(n=99) 
Placebo  
(n=98) 
Efficacy endpoint Valuea 
Effect 
size vs. 
placebo 
(95% CI) 
p-value 
vs.  
placebo Valuea 
Effect size 
vs. placebo 
(95% CI) 
p-value 
vs.  
placebo Valuea 
Effect size 
vs. placebo 
(95% CI) 
p-value 
vs.  
placebo Valuea 
ACR20 response 54 
(54·0%) 
OR 6·81  
(3·42–
13·56) 
<0·0001 51 
(51·0%) 
OR 6·52 
(3·25–13·08) 
<0·0001 29 
(29·3%) 
OR 2·32  
(1·14–4·73) 
0·0399 15 
(15·3%) 
PASI75 response 26/41 
(63·4%) 
OR 9·48  
(3·33–
27·0) 
<0·0001 28/58 
(48·3%) 
OR 5·70  
(2·12–15·34) 
0·0017 14/50 
(28·0%) 
OR 2·07  
(0·74–5·81) 
0·1650 7/43 
(16·3%) 
PASI90 response 20/41 
(48·8%) 
OR 
10·74  
(3·13–
36·84) 
0·0005 19/58 
(32·8%) 
OR 6·36  
(1·89–21·47) 
0·0057 6/50 
(12·0%) 
OR 1·38 
(0·36–5·36) 
0·6421 4/43 
(9·3%) 
DAS28-CRP, LS 
mean change from 
baseline 
–1·61 
(0.11) 
∆ -0·65b  
(-1·02,  
-0·29) 
0·0013 –1·58 
(0·11) 
∆ -0·62 
(-0·98, -0·26) 
0·0057 –1·12 
(0·11) 
∆ -0·16 
(-0·53, 0·20) 
0·6421 –0·96 
(0·15) 
SF36-PCS, LS mean 
change from baseline 
7·25 
(0·74) 
∆ 5·30b  
(2·91–
7·69) 
0·0013 6·39 
(0·73) 
∆ 4·44  
(2·05–6·83) 
0·0057 4·38 
(0·75) 
∆ 2·42  
(0·02–4·83) 
0·6421 1·95 
(0·97) 
HAQ-DI, LS mean 
change from baseline 
–0·56 
(0·05) 
∆ -0·25b  
(-0·40,  
-0·10) 
0·0040 –0·48 
(0·05) 
∆ -0·17 
(-0·32, -0·02) 
0·0555 –0·32 
(0·05) 
∆ -0·01 
(-0·16, 0·15) 
0·9195 –0·31 
(0·06) 
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ACR50 response 35 
(35·0%) 
OR 7·15  
(2·97–
17·22) 
0·0040 35 
(35·0%) 
OR 7·54  
(3·11–18·25) 
0·0555 18 
(18·2%) 
OR 2·91  
(1·15–7·36) 
0·9195 7 (7·1%) 
Resolution of 
dactylitis¶  
52/111 (46·8%) [pooled data; p=0·9195] 
OR (95% CI) for presence of dactylitis vs placebo: 0·23 (0·07–0·72)  
4/27 
(14·8%) 
Resolution of 
enthesitis¶  
76/188 (40·4%) [pooled data; p=0·9195] 
OR (95% CI) for presence of enthesitis vs placebo: 0·29 (0·13–0·65)  
14/65 
(21·5%) 
aData are n (%), n/N (%), or least-square mean (standard error).  
∆, Difference in LS mean change vs. placebo (95% CI). 
OR and 95% CI are from a logistic regression model with treatment and randomization stratum (anti-TNF-naive or anti-TNF-IR) as factors 
and baseline weight as a covariate; OR >1 favors secukinumab.  
LS mean and 95% CI are from a mixed model repeated measures with treatment regimen, analysis visit and randomization stratum (anti-
TNF status -naive or -IR) as factors, weight and baseline score as continuous covariates, and treatment by analysis visit and baseline 
score by analysis visit as interaction terms, as well as an unstructured covariance structure. 
All cited p-values are versus placebo and are adjusted for multiplicity. 
PASI responses were assessed in patients with ≥3% BSA affected by psoriasis at baseline. 
Resolution of dactylitis and enthesitis was assessed only in those patients with these symptoms at baseline. Improvements in dactylitis 
and enthesitis with secukinumab (pooled) versus placebo were not statistically significant using the hierarchical analysis since the testing 
strategy required all other endpoints on all doses to be significant in order to test, and this requirement was not met. 
ACR = American College of Rheumatology; BSA = body surface area; CI, confidence interval; DAS28-CRP = disease activity score 28 
based on C-reactive protein; HAQ-DI = health assessment questionnaire disability index; LS, least-square; OR, odds ratio; PASI = 
psoriasis area and severity index; SE, standard error; SF36-PCS = short form 36 physical component summary. 
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Table 3: Efficacy of secukinumab at week 24 in anti–TNF-naïve and anti–TNF-IR patients 
 Secukinumab 300 mg Secukinumab 150 mg Secukinumab 150 mg  
Efficacy endpointa Valuea 
Effect size 
vs. 
placebo 
(95% CI) 
p-value 
vs.  
placebo Valuea 
Effect size 
vs. 
placebo 
(95% CI) 
p-value  
vs.  
placebo Valuea 
Effect size 
vs. 
placebo 
(95% CI) 
p-value  
vs. 
placebo Placebo 
Anti–TNF-naïve 
patients  
         
ACR20 response 39/67 (58·2)  
OR 7·77  
(3·36–
17·98) 
0·0040 
40/63 (63·5) 
OR 9·99  
(4·22–
23·66) 
<0·0001 24/65 (36·9) 
OR 3·17  
(1·36–
7.40) 
0·0075 10/63 (15·9) 
ACR50 response 26/67 (38·8) 
OR 9·72  
(3·14–
30·09) 
<0·0001 28/63 (44·4) 
OR 12·54  
(4·03–
39·05) 
<0·0001 16/65 (24·6) 
OR 4·90  
(1·53–
15·64) 
0·0074 4/63 (6·3) 
ACR70 response 15/67 (22·4) 
OR 9·72  
(3·14–
30·09) 
0·0003 17/63 (27·0) 
 
<0·0001 4/65 (6·2) 
 
0·3654 1/63 (1·6) 
PASI75 responseb 19/30 (63·3) 
OR 7·96  
(2·42– 0·0006 20/36 (55·6) 
OR 6·33  
(1·99–
20·15) 
0·0018 10/33 (30·3) 
OR 1·94  
(0·59–
6·34) 
0·2729 6/31 (19·4) 
PASI90 responseb 16/30 (53·3) 
OR 13·11  
(3·09–
55·59) 
0·0005 14/36 (38·9) 
OR 8·09  
(1·92–
34·09) 
0·0044 4/33 (12·1) 
OR 1·40  
(0·28–
7·02) 
0·6825 3/31 (9·7) 
Anti–TNF-IR patients           
ACR20 response 15/33 (45·5) 
OR 4·97  
(1.05–
18·26) 
0·0077 11/37 (29·7) 
OR 2·55  
(0.78–8·32) 0·1216 5/34 (14·7) 
OR 1·03  
(0.27–
3·95) 
0·9639 5/35 (14·3) 
ACR50 response 9/33 (27·3) 
OR 4·37  
(3·14–
30·09) 
0·0431 7/37 (18·9) 
OR 2·39 
(0.56–
10·15) 
0·2374 2/34 (5·9) 
OR 0·69 
(0.11–
4·42) 
0·6941 3/35 (8·6) 
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ACR70 response 5/33 (15·2)  0·0228 4/37 (10·8)  0·1151 2/34 (5·9)  0·2391 0/35 (0·0) 
PASI75 responseb 7/11 (63·6) 
OR 19·29  
(1·77–
210·18) 
0·0152 8/22 (36·4) 
OR 6·17  
(0·66–
57·30) 
0·1094 4/17 (23·5) 
OR 3·46  
(0·33–
36·06) 
0·2986 1/12 (8·3) 
PASI90 responseb 4/11 (36·4) 
OR 6·43  
(0·58–
70·74) 
0·1282 5/22 (22·7) 
OR 3·50  
(0·35–
34·91) 
0·2859 2/17 (11·8) 
OR 1·37  
(0·11–
17·30) 
0·8098 1/12 (8·3) 
Data are n (%), n/N (%). 
aMissing data were imputed as non-response. P-values not adjusted for multiplicity of testing. 
bPASI responses were assessed in patients with ≥3% BSA affected by psoriasis at baseline. 
ACR = American College of Rheumatology; BSA = body surface area; PASI = psoriasis area and severity index; TNF = tumor necrosis factor. 
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Table 4: Safety and tolerability profile of secukinumab through week 16 (placebo-controlled period) and across the entire treatment 
period*  
Variable Through week 16 (placebo-controlled period)  Entire treatment period* 
 
Secukinumab                
300 mg  
(n=100) 
Secukinumab                
150 mg  
(n=100) 
 
Secukinumab                 
75 mg  
(n=99) 
Placebo  
(n=98) 
 Any 
secukinumab                 
300 mg  
(n=145) 
Any 
secukinumab                 
150 mg  
(n=143) 
 
Secukinumab                 
75 mg  
(n=99) 
Placebo 
(n=98) 
 Number of patients with event (%)  
Number of patients with event 
(number of events per 100 patient-years) 
Any AE 56 (56·0) 57 (57·0) 48 (48·5) 57 (58·2)  113 (189·1) 117 (209·0) 77 (175·3) 61 (323·5) 
Serious AE 5 (5·0) 1 (1·0) 4 (4·0) 2 (2·0)  10 (6·4) 8 (5·1) 12 (11·2) 3 (8·6) 
Death 0 0 0 0  0 0 0 0 
Discontinuation of 
study treatment 
due to any AE 
2 (2·0) 0 2 (2·0) 3 (3·1)  3 (2·1) 4 (2·8) 4 (4·0) 4 (4·1) 
Infection or 
infestation 29 (29·0) 30 (30·0) 23 (23·2) 30 (30·6)  78 (78·7) 82 (86·7) 48 (63·7) 30 (108·0) 
Common AEs¶         
Upper 
respiratory tract 
infection 
4 (4·0) 8 (8·0) 10 (10·1) 7 (7·1)  26 (17·9) 25 (17·6) 21 (21·8) 7 (20·7) 
Nasopharyngitis 6 (6·0) 4 (4·0) 6 (6·1) 8 (8·2)  20 (13·5) 18 (12·3) 11 (10·5) 8 (24·2) 
Diarrhea 2 (2·0) 2 (2·0) 3 (3·0) 3 (3·1)  10 (6·3) 8 (5·1) 8 (7·4) 3 (8·8) 
Headache 7 (7·0) 4 (4·0) 2 (2·0) 4 (4·1)  9 (5·9) 10 (6·5) 5 (4·6) 5 (14·9) 
Nausea 3 (3·0) 4 (4·0) 4 (4·0) 4 (4·1)  7 (4·5) 8 (5·2) 6 (5·6) 4 (11·9) 
Sinusitis 1 (1·0) 2 (2·0) 0 1 (1·0)  10 (6·5) 6 (3·8) 5 (4·6) 1 (2·9) 
Psoriatic 
arthropathy 0 3 (3·0) 1 (1·0) 2 (2·0)  5 (3·1) 10 (6·5) 6 (5·5) 2 (5·8) 
Urinary tract 
infection 2 (2·0) 4 (4·0) 1 (1·0) 4 (4·1)  6 (3·8) 6 (3·9) 4 (3·6) 4 (11·8) 
Hematuria 2 (2·0) 3 (3·0) 1 (1·0) 1 (1·0)  2 (1·3) 4 (2·5) 3 (2·7) 1 (2·9) 
Vomiting 2 (2·0) 2 (2·0) 2 (2·0) 1 (1·0)  3 (1·9) 4 (2·5) 4 (3·6) 2 (5·8) 
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*The entire treatment period was defined as the period from baseline up to the week 52 visit of the last patient enrolled in the study.  
‡Exposure-adjusted incidence rates were not calculated for discontinuations due to AEs. Percentages are shown in parentheses. 
¶The most common AEs are expressed according to the preferred term in the Medical Dictionary for Regulatory Activities, and occurred in 
≥2·0% of patients in the pooled secukinumab group through week 16 or at an incidence rate of ≥5·0 per 100 patient-years in the pooled 
secukinumab group during the entire treatment period. 
AE = adverse event; SD = standard deviation. 
